NCT00694161 - The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Cardiomyopathy

Interventions

DRUG

Fx-1006A

Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months

Trial Locations (6)

Columbia University, New York

Johns Hopkins Hospital, Baltimore

Emory University School of Medicine, Atlanta

Mayo Clinic, Rochester

University of Chicago, Chicago

Harvard Vanguard Medical Associates, Boston